Missed us at EANM 2026 in Vienna? Catch up on demand
Thank you to everyone who visited us at EANM 2026. If you couldn’t make it to Vienna, you can now watch our videos, download the presentation and posters, and read the latest EPIC-Skin publication.
The congress provided an opportunity to connect with the international nuclear medicine community and exchange insights on Rhenium-SCT, clinical evidence and the evolving role of targeted cutaneous radioisotope therapy in the treatment of non-melanoma skin cancer.
Explore our EANM 2026 resources below, including scientific presentations, educational materials, videos and further information about OncoBeta and Rhenium-SCT.
Video:
EANM 2026 Recap
Highlights from our time at EANM 2026 in Vienna.
Publication:
Baxi S, et al. 188Rhenium skin cancer therapy: Two-year efficacy, safety and patient-reported outcomes from the prospective, multicentre, phase IV, EPIC-skin study in non-melanoma skin cancer. EANM Innovation 2026; 5:100311.
Read the full paper (open access)
Video:
Dose modelling and application variability in Rhenium-SCT®
Presentation by F. Martin del Rosario: Monte Carlo investigation of dose modelling and application variability in rhenium-188 skin radionuclide therapy.
Video:
Building Bridges at EANM 2026: Multidisciplinary Management of Non-Melanoma Skin Cancer
Educational dinner with Dr. Sylvia Holle-Robatsch, MD (Vienna), Patient Selection, Referral Pathways and Follow-Up Care in Non-Melanoma Skin Cancer: The Dermatologist’s Perspective, and Prof. Siroos Mirzaei, MD (Vienna), Real-world experience with Rhenium-SCT and multidisciplinary patient selection in non-melanoma skin cancer from Vienna.
Presentation:
Monte Carlo investigation of dose modelling and application variability in rhenium-188 skin radionuclide therapy
Poster:
Rhenium-188 skin cancer therapy (SCT) European Subanalysis: Two-year efficacy and safety from a prospective multicentre phase IV study
Poster:
Rhenium-188 skin cancer therapy: two-year efficacy and safety from a prospective multicenter phase IV study with dermatology-directed assessment of skin findings (EPIC-Skin Trial)
Explore:
Explore Clinical evidence
Review published data, ongoing evidence generation initiatives and scientific publications supporting Rhenium-SCT®.
Explore:
Understand the Technology
Visit the Technology Hub to learn more about epidermal radionuclide therapy and the scientific principles behind Rhenium-SCT®.
This content is intended only for healthcare professionals practicing in regions where Rhenium-SCT® is approved.